Use of common pesticide, imidacloprid, linked to bee colony collapse

We know that, Imidacloprid is a systemic insecticide which acts as an insect neurotoxin and belongs to a class of chemicals called the neonicotinoids which act on the central nervous system of insects with much lower toxicity to mammals. The chemical works by interfering with the transmission of stimuli in the insect nervous system. Specifically, it causes a blockage in a type of neuronal pathway (nicotinergic) that is abundant in insects and not in warm-blooded animals (making the chemical selectively toxic to insects and not warm-blooded animals). This blockage leads to the accumulation of acetylcholine, an important insect neurotransmitter, resulting in the insect's paralysis, and eventually death. It is effective on contact and via stomach action

Use of common pesticide, imidacloprid, linked to bee colony collapse: The likely culprit in sharp worldwide declines in honeybee colonies since 2006 is imidacloprid, one of the most widely used pesticides, according to a new study.

Immunotherapy and Chemotherapy Regimen May Prolong Survival in Advanced Cancers

In continuation of my update on interleukin and retinoic acid

Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don't get the combination. 

Retinoic acid is derived from vitamin A. Interleukin-2, a compound that fortifies the immune system, is approved at high doses to treat "metastatic" melanoma and kidney cancer. Metastatic means that a cancer has spread.

The study showed that "these biological compounds may work at low doses. Bigger doses are not always better," said lead author Dr. Francesco Recchia, director of the oncology department at Civilian Hospital in Avezzano, Italy.

Recchia stumbled upon the possibility of using low-dose interleukin-2 (IL-2) when he switched a patient with metastatic melanoma who didn't tolerate high doses to a lower dose, and the patient had an extended response to the therapy.

This study involved 500 patients who had already responded well to chemotherapy. They had a variety of cancers, including ovarian, lung, colon, stomach, kidney, melanoma, breast and pancreatic.

Immunotherapy and Chemotherapy Regimen May Prolong Survival in Advanced Cancers

Berries, Tea May Cut Men's Odds for Parkinson's: Study

In continuation of my update on the benefits of   berries, apple, tea...

Berries, Tea May Cut Men's Odds for Parkinson's: Study:  - Regularly consumption of food and drink rich in substances called flavonoids, such as berries, apples, tea and red wine, can lower a man's risk of developing Parkinson's disease by 40 percent, new research suggests.

Antipsychotic drug may be helpful treatment for anorexia nervosa

In continuation of my update on Olanzapine...

Antipsychotic drug may be helpful treatment for anorexia nervosa

Cruciferous vegetable intake may boost survival of breast cancer patients

In continuation of my update on Broccoli and cabbage

Researchers with Vanderbilt-Ingram Cancer Center and the Shanghai Cancer Institute in China have discovered a possible link between a diet rich in certain vegetables and a decreased risk for breast cancer.

Corresponding author Jay Fowke, Ph.D., assistant professor of Medicine, said 3,035 women diagnosed with breast cancer were identified through the Shanghai Cancer Registry. They were closely matched with 3,037 women randomly chosen from the general population.

Ref : http://www.vicc.org/news/2008/03/study-tracks-link-between-cancer-vegetables/

Experimental Cholesterol Drug Could Be 'Game Changing'

 Initially, I was reluctant about  "Monoclonal antibody therapy". Recently  there is surge of interest in " human monoclonal antibodies". 

History behind this surge : The idea of a "magic bullet" was first proposed by Paul Ehrlich, who, at the beginning of the 20th century, postulated that, if a compound could be made that selectively targeted against a disease-causing organism, then a toxin for that organism could be delivered along with the agent of selectivity. He and Élie Metchnikoff received the 1908 Nobel Prize for Physiology or Medicine for this work, which led to an effective syphilis treatment by 1910....

Experimental Cholesterol Drug Could Be 'Game Changing': Experimental Cholesterol Drug Could Be 'Game Changing' [St.Joseph News-Press (Mo)] From St. Joseph News-Press (MO) (March 22, 2012) (CNN) -- A new, experimental cholesterol-fighting drug is creating quite a buzz among researchers and other...

FDA Approves First Boniva Generics to Treat Or Prevent Osteoporosis

FDA Approves First Boniva Generics to Treat Or Prevent Osteoporosis: The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after

menopause. The most common type of bone disease...

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer — NEJM

We know that Olaparib, is a experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by Astra Zeneca, that failed to progress through clinical trials to approval. It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast and prostate  

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer — NEJM

FDA Approves Intelence (Etravirine) for Pediatric Patients...

U.S. Food and Drug Administration (FDA) has approved Intelence (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6 years to <18 years old) who are experiencing virologic failure with HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other ARVs.

This approval, which follows FDA priority review of the company’s supplemental New Drug Application, expands the Intelence indication and makes it the only NNRTI indicated for this use in both treatment-experienced children and adults with resistance to an NNRTI and other ARVs. The approval includes a new 25mg dose to allow for weight-based dosing in pediatric patients (6 years to <18 years old and weighing at least 16kg or 35.2 lbs). The 25mg tablet is expected to be available in the first half of May.

Ref : http://www.janssentherapeutics.com/news-center/fda-approves-edurant-rilpivirine-for-use-in-treatment-naive-adults-with-hiv

Paclitaxel drug slows damage and symptoms in (Alzheimer's disease) animal model

A compound,  epothilone D (EpoD) that previously progressed to Phase II clinical trials for cancer treatment slows neurological damage and improves brain function in an animal model of Alzheimer's disease, according to a new study.  Compound is effective in preventing further neurological damage and improving cognitive performance in a mouse model of Alzheimer's disease (AD). The results establish how the drug might be used in early-stage AD patients......

Potential Alzheimer's disease drug slows damage and symptoms in animal model

Healthy lactic acid bacteria in wild honey bees can fight bacterial infections

In continuation of my update on the usefulness of honey...

Healthy lactic acid bacteria in wild honey bees can fight bacterial infections: The stomachs of wild honey bees are full of healthy lactic acid bacteria that can fight bacterial infections in both bees and humans. A collaboration between researchers at three universities in Sweden ¬- Lund University, the Swedish University of Agricultural Sciences and Karolinska Institutet - has produced findings that could be a step towards solving the problems of both bee deaths and antibiotic resistance...

A New Approach to Faster Anticancer Drug Discovery

A new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug Peruvoside (see below structure) currently marketed for congestive heart failure.  

A New Approach to Faster Anticancer Drug Discovery

Researchers unlock mystery of how an inflammatory molecule is produced in the body

Researchers unlock mystery of how an inflammatory molecule is produced in the body: Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness: The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158 (see below structure) , to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

Ref : http://www.dndi.org/press-releases/1169-oxa-phasei.html

Antidepressant, TCP (Trabylcypromine) could help the workings of anticancer drug used in leukemia...

A new study shows that an antidepressant could be crucial in helping cancer treatment drugs reach their full potential.

The study by scientists at the Institute of Cancer Research found that tranylcypromine (TCP - cis and trans iosmers - below structures) – which can be used to treat psychotic depressive states - can make cancer cells vulnerable to the effects of a vitamin A- derivative drug called ATRA (above structure).

Retinoids are a class of chemical compounds related chemically to vitamin A. ATRA is already used successfully to treat a rare form of acute myeloid leukemia (AML), but up until now, has not been effective against other types of the disease. ATRA works by encouraging leukemia cells to mature and die naturally, but the researchers lead by Ar. Arthur Zelent say that the reason many AML patients do not respond to the treatment is because the genes that ATRA normally attacks are switched off by an enzyme called LSD1. The scientists discovered that using TCP to block this 'off switch' could reactivate these genes, making the cancer cells susceptible to ATRA.

The team has already joined forces with the University of Munster in Germany to start a Phase II clinical trial of the drug combination in AML patients. The authors also commented that both the retinoid ATRA and the antidepressant TCP are already available in the UK and off-patent, so these drugs should not be expensive for the health service. 

Ref : http://www.icr.ac.uk/research/new_research_highlights/research_highlights/22625.shtml